What is the appropriate management for pruritic erythema of the palms?

Management of Pruritic Erythema of the Palms

Start with intensive topical corticosteroids under occlusion, and if this fails to achieve adequate control, escalate to systemic therapy with oral retinoids (acitretin) or photochemotherapy (PUVA), as palmoplantar disease significantly impairs quality of life and justifies systemic treatment despite limited body surface area involvement. 1

Diagnostic Considerations

Before initiating treatment, determine the underlying etiology of palmar erythema and pruritus:

• Palmoplantar psoriasis presents with erythematous, scaly, fissured hyperkeratotic plaques that significantly impact hand function and ambulation 1
• Palmar-plantar erythrodysesthesia (PPES) from chemotherapy agents (5-fluorouracil, capecitabine, liposomal doxorubicin) manifests as dysesthesia, tingling, burning pain with erythema, potentially progressing to desquamation and ulceration 1, 2
• Secondary palmar erythema may indicate liver cirrhosis (23% of cases), rheumatoid arthritis (>60%), thyrotoxicosis (18%), diabetes mellitus (4.1%), or malignancy (15% with brain tumors) 3, 4
• Pompholyx (dyshidrotic eczema) presents as vesicobullous eruptions on palms and soles 5

Treatment Algorithm for Palmoplantar Psoriasis

First-Line: Intensive Topical Therapy

• High-potency topical corticosteroids (clobetasol 0.05%) applied twice daily under occlusion 1
• Continue for 2-4 weeks and reassess response 1
• Calcineurin inhibitors may serve as steroid-sparing alternatives 5

Second-Line: Phototherapy

When topical therapy proves insufficient:

• Topical PUVA (soak PUVA): Soak palms/soles in methoxsalen solution for 15-30 minutes before UVA exposure, 2-3 times weekly for several months 1
• Oral PUVA: First-line PUVA treatment for palmoplantar dermatoses, though carries long-term cutaneous malignancy risk on sun-exposed skin 1
• Targeted phototherapy: 308-nm excimer laser as alternative 1
• Note: Cutaneous malignancy on palms/soles after topical PUVA is very rare 1

Third-Line: Systemic Therapy

Systemic therapy is strongly justified when topical therapy and photochemotherapy fail, as palmoplantar psoriasis disproportionately impacts quality of life relative to body surface area affected. 1

Oral Retinoids (Preferred)

• Acitretin 25 mg daily: Demonstrated substantial improvement within 2 months in palmoplantar psoriasis with significant quality of life enhancement 1
• Dose reduction to 25 mg on alternate days often possible after initial response 1
• Monitor lipids (triglycerides/cholesterol elevations manageable with fibrates and/or statins) 1
• Caution: Avoid simultaneous fibrates and statins due to rhabdomyolysis risk 1
• Combination therapy: Acitretin + topical PUVA reduces treatment number and potentially decreases skin malignancy risk 1

Alternative Systemic Options

• Methotrexate (MTX): Effective but requires monitoring for hepatotoxicity and bone marrow toxicity 1
• Cyclosporine: Effective but monitor for nephrotoxicity 1
• Biologic agents: Adalimumab, infliximab show promise for palm/sole psoriasis, though formal trial results remain unpublished 1

Fourth-Line: Combination Therapy

For refractory cases:

• Acitretin + Biologic agent
• Cyclosporine + MTX
• Intermittent cyclosporine + Biologic
• MTX + Biologic 1

Management of Chemotherapy-Induced PPES

Prevention

• Behavioral modifications: Avoid mechanical stress (prolonged walking, heavy carrying without cushioned shoes/gloves), chemical irritants, excessive sun exposure 1
• Urea 10% cream applied at least twice daily 1
• Cooling hands/feet during infusions (for paclitaxel, docetaxel, liposomal doxorubicin) significantly reduces PPES frequency and severity 1

Treatment by Grade

Grade 1-2:

• Continue chemotherapy at current dose 1
• High-potency topical corticosteroid (clobetasol 0.05%) twice daily 1
• Cooling during infusions 1
• Reassess after 2 weeks; escalate if worsening 1

Grade ≥3 or intolerable Grade 2:

• Interrupt chemotherapy until severity decreases to Grade 0-1 1
• High-potency topical corticosteroid twice daily 1
• Keratolytics (salicylic acid 5-10% or urea 10-40%) for hyperkeratosis 1
• Antiseptic solutions (silver sulfadiazine 1%) for erosions/ulcerations 1
• Lidocaine 5% cream/patches for analgesia 1

Common Pitfalls

• Do not dismiss palmoplantar disease as minor based on limited body surface area—quality of life impact justifies aggressive systemic therapy 1
• Avoid pyridoxine for PPES prevention—well-designed studies show no benefit 1
• Monitor for paradoxical psoriasis development with TNF-alpha antagonists, particularly pustular palmoplantar variants 1
• Screen for secondary causes of palmar erythema (liver disease, malignancy, endocrinopathies) before attributing to primary dermatologic conditions 3, 4
• Minimize total PUVA treatments to reduce long-term skin cancer risk, particularly squamous cell carcinoma on sun-exposed areas 1